Abstract:Background Cancer is a heterogeneous disease caused by genomic aberrations and characterized by significant variability in clinical outcomes and response to therapies. Several subtypes of common cancers have been identified based on alterations of individual cancer genes, such as HER2, EGFR, and others. However, cancer is a complex disease driven by the interaction of multiple genes, so the copy number status of individual genes is not sufficient to define cancer subtypes and predict responses to treatments. A classification based on genome-wide copy number patterns would be better suited for this purpose. Method To develop a more comprehensive cancer taxonomy based on genome-wide patterns of copy number abnormalities, we designed an unsupervised classification algorithm that identifies genomic subgroups of tumors. This algorithm is based on a modified genomic Non-negative Matrix Factorization (gNMF) algorithm and includes several additional components, namely a pilot hierarchical clustering procedure to determine the number of clusters, a multiple random initiation scheme, a new stop criterion for the core gNMF, as well as a 10-fold cross-validation stability test for quality assessment. Result We applied our algorithm to identify genomic subgroups of three major cancer types: non-small cell lung carcinoma (NSCLC), colorectal cancer (CRC), and malignant melanoma. High-density SNP array datasets for patient tumors and established cell lines were used to define genomic subclasses of the diseases and identify cell lines representative of each genomic subtype. The algorithm was compared with several traditional clustering methods and showed improved performance. To validate our genomic taxonomy of NSCLC, we correlated the genomic classification with disease outcomes. Overall survival time and time to recurrence were shown to differ significantly between the genomic subtypes. Conclusions We developed an algorithm for cancer classification based on genome-wide patterns of copy number aberrations and demonstrated its superiority to existing clustering methods. The algorithm was applied to define genomic subgroups of three cancer types and identify cell lines representative of these subgroups. Our data enabled the assembly of representative cell line panels for testing drug candidates.

Tumor Sub-types Discovery Model Based on Hierarchical Clustering Algorithm

Effective cancer subtyping by employing density peaks clustering by using gene expression microarray

Cancer Subtype Discovery and Biomarker Identification Via a New Robust Network Clustering Algorithm.

Gene Selection for Cancer Clustering Analysis Based on Expression Data

Subtype Dependent Biomarker Identification and Tumor Classification from Gene Expression Profiles.

Application of New Clustering Algorithms in Gene Expression Data

Unraveling the hidden heterogeneities of breast cancer based on functional miRNA cluster.

Cancer Subtype Recognition and Feature Selection with Gene Expression Profiles

Application of Betweenness Clustering Algorithm in Cancer Gene Expression Profiles

An Integrated Approach for Identifying Molecular Subtypes in Human Colon Cancer Using Gene Expression Data

Using Gene Ontology-based clustering method to study the genetic heterogeneity of leukemia

Kernel Fusion Method for Detecting Cancer Subtypes via Selecting Relevant Expression Data.

A unified computational model for revealing and predicting subtle subtypes of cancers

Clustering of Transcriptomic Data for the Identification of Cancer Subtypes

Neighborhood Rough Set Model Based Gene Selection for Multi-subtype Tumor Classification

Clustering cancer gene expression data: a comparative study

FEATURE SELECTION FOR CLUSTERING DISEASE SAMPLES BASED ON GENE ONTOLOGY

[Analysis of Diffuse Large B-cell Lymphoma Heterogeneity Based on Coupled Two-Way Clustering].

Selection of Feature Genes in Cancer Clsssification

Low Rank Subspace Clustering Via Discrete Constraint and Hypergraph Regularization for Tumor Molecular Pattern Discovery

An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models